Medical Weight Loss: The Science Behind GLP-1 and Metabolic Care

Medical weight loss has shifted dramatically over the past five years. The arrival of GLP-1 receptor agonists — semaglutide, tirzepatide, and related compounds — has given physicians their first reliable pharmacological lever for sustained weight reduction at scale. This article unpacks how these therapies work, what the published evidence actually shows, and how candidate evaluation should be done at a physician-led clinic.

This is an information-layer article. It is not a substitute for the personalised assessment that takes place during a consultation with Dr. Charles Jiang at Richmond Anti-Aging Clinic (RAAC) in Richmond, BC, Canada. For program details and pricing, visit our medical weight loss service page.

Mechanism of Action: How GLP-1 Agonists Reset Energy Balance

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the ileum and colon in response to nutrient intake. Endogenous GLP-1 has a half-life of just a few minutes — it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Pharmaceutical analogues are engineered to resist this degradation, extending receptor activity from minutes to days.

The weight-relevant actions occur on at least three fronts:

1. Central appetite suppression. GLP-1 receptors are expressed in the arcuate nucleus and brainstem nuclei that regulate satiety. Activation reduces hunger signalling and increases meal-end satisfaction. Functional MRI studies have shown reduced reward-system activation in response to food cues.
2. Delayed gastric emptying. Stomach contents pass into the small intestine more slowly, prolonging the sensation of fullness from a given meal volume.
3. Improved insulin sensitivity and glycemic control. GLP-1 enhances glucose-dependent insulin secretion and suppresses glucagon, which is why these drugs were first approved for type 2 diabetes before their weight indication.

Tirzepatide, a dual GIP/GLP-1 agonist, recruits a second incretin pathway and has shown additional efficacy in head-to-head comparisons.

Clinical Evidence: What the Trials Actually Show

The regulatory and clinical literature for these molecules is unusually mature. Three trial programs anchor the evidence base:

• STEP (Wilding et al., New England Journal of Medicine). Semaglutide 2.4 mg weekly produced a mean 14.9% body-weight reduction at week 68 versus 2.4% for placebo, with both arms receiving lifestyle intervention.
• SURMOUNT (Jastreboff et al., NEJM). Tirzepatide 15 mg weekly produced mean reductions of 20.9% at the highest dose, with a substantial proportion of participants achieving ≥25% weight loss.
• SUSTAIN cardiovascular outcomes program (Marso et al., NEJM). Established cardiovascular safety in type 2 diabetes populations, supporting the broader use case.

These are means. Individual response varies. A physician's job is partly to reset expectations: not everyone reaches the upper percentile, and not everyone tolerates the highest dose.

GLP-1 agonists are approved by Health Canada and the U.S. FDA for chronic weight management in eligible adults. Approval status, indications, and labelled dosing are the regulator's domain — not marketing copy.

How This Compares to Adjacent Mechanisms

It is worth situating GLP-1 therapy among other tools, because the patient question is rarely "should I take semaglutide?" — it is "what is the right approach for my body?"

• Behavioural intervention alone produces modest mean weight loss (typically 3-5%). Effective for some, insufficient for most adults with established obesity.
• Bariatric surgery remains the most effective intervention for severe obesity (BMI ≥40) but carries operative risk and irreversible anatomic change.
• Body-contouring procedures (CoolSculpting, EMSculpt NEO) are not weight-loss tools. They reduce localised subcutaneous fat in already-lean patients. They do not move the BMI needle and are inappropriate as a substitute for medical weight management.

A candid clinic conversation matches mechanism to goal. GLP-1 therapy is for systemic weight loss; device-based contouring is for stubborn local fat after weight is stabilised.

Candidate Evaluation: Who Should and Shouldn't Pursue This

Not every patient is a good candidate for GLP-1 therapy. Standard medical eligibility criteria include:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea).
• Absence of contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome, prior pancreatitis, severe gastroparesis.
• Capacity for sustained engagement: pharmacotherapy is most effective alongside nutritional support and physical activity. Patients who plan to use medication as a sole strategy tend to regain weight after discontinuation.
• Realistic expectations about pace (gradual), magnitude (mean 15-20%, not 50%), and duration (likely chronic management, like a blood-pressure medication).

At RAAC, this evaluation is conducted by Dr. Charles Jiang (CPSBC registered, 29+ years of clinical experience). It includes a metabolic panel, weight history, medication review, and goal-setting conversation. Patients with red flags are referred to endocrinology or bariatric services rather than enrolled in our program.

Limitations, Side Effects, and What the Trials Don't Say

A responsible discussion includes the known limitations:

• Gastrointestinal side effects (nausea, constipation, occasional vomiting) are common during dose escalation. They are usually transient and managed with slow titration. A small minority discontinue therapy for tolerability.
• Muscle mass loss. A portion of total weight reduction is lean tissue. Resistance training and adequate protein intake during the active loss phase are not optional — they are part of a competent program.
• Weight regain after discontinuation. Trial extension data show that stopping the drug is followed by gradual regain. This is consistent with how the body defends against weight loss generally; it is not a failure of the medication.
• Compounded versus brand-name product quality. Patients should ask where their medication is sourced. Compounded semaglutide does not have the same regulatory oversight as the FDA / Health Canada-approved branded product.

Frequently Asked Questions

How long does a typical program last? Clinical guidelines treat obesity as a chronic condition. Some patients use medication for 6-12 months to reach a target weight and then transition to a maintenance phase with reduced dosing or alternative strategies. Others continue indefinitely. The decision is individualised.

Can I just lose weight with diet and exercise? For some people, yes. For adults with established obesity, the published mean response to lifestyle intervention alone is 3-5% — meaningful but often insufficient. GLP-1 agonists are intended for patients who have not achieved adequate response with lifestyle measures alone and who meet eligibility criteria.

Is this covered by BC MSP? GLP-1 agonists for weight management are generally not covered by provincial plans for the obesity indication. Some private insurance plans provide partial coverage. Contact us for current pricing.

Will I keep the weight off after stopping? Long-term cohort data suggest gradual regain is typical without continued behavioural support. Programs that pair pharmacotherapy with nutritional and activity support produce better maintenance outcomes than medication alone.

What about other tools like CoolSculpting? Local fat reduction technologies are not weight-loss tools. They are appropriate after weight is stabilised, for residual stubborn deposits, and only in patients near their target weight.

Why Choose RAAC for Medical Weight Loss

Richmond Anti-Aging Clinic is a physician-led clinic in Richmond, British Columbia, Canada (not Richmond, Virginia). Dr. Charles Jiang is a CPSBC-registered physician with over 29 years of clinical experience. Programs include a baseline metabolic assessment, individualised dosing under physician supervision, monthly check-ins, and integrated lifestyle coaching. Bilingual care is available in English and Mandarin. Book a consultation to determine whether you are a candidate.

Next Steps

If you are weighing your options, the most useful next step is a one-on-one assessment rather than further reading. Bring your medical history, current medications, and a sense of what "success" would look like for you. Schedule your consultation today — we will give you an honest read on fit, expected magnitude of response, and program structure.

This article is for educational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional before undergoing any treatment.